[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) for Human Immunodeficiency Virus (HIV) Infection
Phase-Based Progress Estimates
Effectiveness
Safety
Human Immunodeficiency Virus (HIV) Infection[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) - Drug
Study Summary
This trial is exploring the use of a new PET tracer to study HIV in the body. It will enroll people who are early or late in their infection, or who are not on treatment.
Eligible Conditions
- Human Immunodeficiency Virus (HIV) Infection
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 1-4 hours
1-2 weeks
Correlate [18F]F-AraG uptake with measures of HIV persistence
1-4 hours
Anatomical distribution of [18F]F-AraG
[18F]F-AraG uptake in early and later-treated HIV infection
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
[18F]F-AraG
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) · No Placebo Group · Phase 1
[18F]F-AraG
Drug
Experimental Group · 1 Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) · Intervention Types: DrugTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1-4 hours
Who is running the clinical trial?
CellSight Technologies, Inc.Lead Sponsor
15 Previous Clinical Trials
267 Total Patients Enrolled
University of California, San FranciscoOTHER
2,283 Previous Clinical Trials
11,577,744 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,153 Previous Clinical Trials
4,770,935 Total Patients Enrolled
Timothy J Henrich, MDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
10 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:References
- Ronald, John A., Byung-Su Kim, Gayatri Gowrishankar, Mohammad Namavari, Israt S. Alam, Aloma D'Souza, Hidekazu Nishikii, et al.. 2017. “A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-host Disease Elicited by Allogenic Hematopoietic Cell Transplant”. Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/0008-5472.can-16-2953.
- Franc, Benjamin L., Sam Goth, John MacKenzie, Xiaojuan Li, Joseph Blecha, Tina Lam, Salma Jivan, Randall A. Hawkins, and Henry VanBrocklin. 2017. “In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis”. Molecular Imaging. SAGE Publications. doi:10.1177/1536012117712638.
- 2018. "Imaging Immune Activation in HIV by PET-MR". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03684655.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments